Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $137.00 | Outperform | RBC Capital Mkts |
| 1/28/2026 | $144.00 | Hold → Buy | HSBC Securities |
| 1/14/2026 | $131.00 | Buy → Hold | TD Cowen |
| 12/11/2025 | $176.00 | Buy | UBS |
| 7/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/9/2025 | $142.00 | Buy → Hold | HSBC Securities |
| 6/30/2025 | $150.00 | Overweight | Piper Sandler |
| 5/14/2025 | $150.00 | Equal-Weight → Overweight | Morgan Stanley |
RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00
HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00
TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00
TORONTO and NEW YORK, July 14, 2026 /CNW/ -- Thomson Reuters Corporation (TSX/Nasdaq: TRI) today announced that it has signed a definitive agreement to enter into a joint venture with KKR, a leading global investment firm. As part of the transaction, Thomson Reuters will sell a 51% stake in its Global Print business to capital accounts advised by KKR. Thomson Reuters will receive approximately $500 million in gross proceeds at closing and will retain a 49% equity interest in the joint venture. Thomson Reuters will also maintain intellectual property rights and full editorial control over its content portfolio. This new joint venture will hold an exclusive license to distribute the content in
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt
KKR, a leading global investment firm, today announced its cornerstone investment in a A$400 million (US$275 million) financing solution (the "Financing") for Ampol Limited (ASX: ALD) ("Ampol"), anchored by KKR's private credit and insurance platforms. The investment will support Ampol’s refinancing initiatives and other general corporate purposes, in line with its Capital Allocation Framework. Listed on the ASX, Ampol operates an integrated fuel supply and marketing value chain in Australia that encompasses the Lytton refinery in Queensland, an extensive national network of terminals and pipelines, and a convenience retail footprint of approximately 1,700 sites. Ampol also maintains a si
8-K - KKR & Co. Inc. (0001404912) (Filer)
8-K - KKR & Co. Inc. (0001404912) (Filer)
S-3ASR - KKR & Co. Inc. (0001404912) (Filer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
PHILADELPHIA and NEW YORK, July 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its second quarter 2026 results before the opening of trading on the New York Stock Exchange on Thursday, August 6, 2026. FSK will host its second quarter 2026 results conference call via live webcast on Thursday, August 6, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the foll
KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the second quarter 2026 on Thursday, July 30, 2026, before the opening of trading on the New York Stock Exchange.A conference call to discuss KKR’s financial results will be held on Thursday, July 30, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be avail
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr
Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion. This press release feature
Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential
Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden